Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alam, Md. Maqusood | - |
dc.contributor.author | Hassan, Ahmed H. E. | - |
dc.contributor.author | Kwon, Yeong Ho | - |
dc.contributor.author | Lee, Hyo Jong | - |
dc.contributor.author | Kim, Nam Yong | - |
dc.contributor.author | Min, Kyung Hoon | - |
dc.contributor.author | Lee, Sang-Yoon | - |
dc.contributor.author | Kim, Dong-Hyun | - |
dc.contributor.author | Lee, Yong Sup | - |
dc.date.available | 2019-01-22T14:15:54Z | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1374 | - |
dc.description.abstract | The evolving resistance to the currently used chemotherapeutic agents requires continuous efforts to develop new anticancer agents overcoming resistance and with lower side effects. Polypharmacology via designing a single molecule intercepting multiple signaling pathways is more effective than targeting a single one. Several alkylphosphocholines show anticancer activity via inhibition of Akt phosphorylation. On the other hand, several molecules having quinazoline scaffold elicit anticancer activity through inhibition of epidermal growth factor receptor (EGFR) tyrosine kinases. We report our efforts to develop alkylphosphocholines-gefitinib conjugates as multitarget anticancer agents. The antiproliferative activities of the newly synthesized compounds were evaluated against cell lines representing lung, breast, liver and skin cancers. In addition, the capability of the newly synthesized compounds to inhibit Akt phosphorylation and EGFR tyrosine kinases were determined. The results emphasized the influence of the linkers' length on the elicited bioactivity. The long chain linkers possessing conjugates were more active regarding both of the elicited antiproliferative effect and inhibition of Akt phosphorylation, while maintained the ability to inhibit EGFR tyrosine kinases. Their cytotoxic activities were superior or comparable to erlotinib and miltefosine. | - |
dc.format.extent | 11 | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-017-0977-z | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.41, no.1, pp 35 - 45 | - |
dc.identifier.kciid | ART002310389 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000422801300004 | - |
dc.identifier.scopusid | 2-s2.0-85032808346 | - |
dc.citation.endPage | 45 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 41 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Alkylphosphocholines | - |
dc.subject.keywordAuthor | Gefitinib | - |
dc.subject.keywordAuthor | Akt phosphorylation inhibitors | - |
dc.subject.keywordAuthor | EGFR tyrosine kinase inhibitors | - |
dc.subject.keywordAuthor | Antiproliferartive agents | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | LIPID RAFTS | - |
dc.subject.keywordPlus | AKT PHOSPHORYLATION | - |
dc.subject.keywordPlus | SIGNAL-TRANSDUCTION | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | MILTEFOSINE | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | MEMBRANE | - |
dc.subject.keywordPlus | ALKYLPHOSPHOLIPIDS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.